Mode
Text Size
Log in / Sign up

Staged PCI reduces severe kidney injury risk after TAVR in aortic stenosis and CADStaged heart procedures may lower risk of severe kidney injury

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider staged PCI to reduce severe kidney injury risk in TAVR patients with CAD, but note no overall CI-AKI benefit.

This meta-analysis evaluated the safety of staged versus concomitant percutaneous coronary intervention (PCI) in patients with aortic stenosis and coronary artery disease undergoing transcatheter aortic valve replacement (TAVR). The analysis included 7,119 patients and assessed the incidence of contrast-induced acute kidney injury (CI-AKI) as the primary outcome.

For overall CI-AKI, staged PCI did not significantly differ from concomitant PCI (OR 1.02; 95% CI 0.53 to 1.98; p = 0.959). Similarly, no significant differences were observed for stage 1 CI-AKI (OR 1.99; 95% CI 0.38 to 10.47; p = 0.417) or stage 2 CI-AKI (OR 1.01; 95% CI 0.39 to 2.64; p = 0.978). However, for stage 3/4 CI-AKI, staged PCI showed a statistically significant benefit (OR 0.48; 95% CI 0.24 to 0.99; p = 0.046).

The authors noted observed heterogeneity as a limitation. The findings suggest that staged PCI may offer potential benefits for preventing more severe kidney injury (stages 3/4) in this population, but does not consistently reduce overall CI-AKI. Clinicians should weigh these results against individual patient risk factors and procedural considerations.

How this fits prior evidence

This meta-analysis extends prior coverage on TAVR outcomes by addressing the PCI timing strategy. While prior coverage highlighted general anesthesia risks and machine learning mortality prediction in TAVR, this analysis focuses on kidney injury prevention. The finding that staged PCI reduces stage 3/4 CI-AKI (OR 0.48) contrasts with the lack of benefit for overall CI-AKI, suggesting a potential role in severe cases. It does not directly confirm or contradict prior findings on DAPT or educational interventions.

When patients undergo a TAVR procedure to treat aortic stenosis, they often have underlying coronary artery disease as well. Doctors must decide whether to perform both treatments at once or space them out, which is called a staged approach. This choice matters because the contrast dye used during these procedures can sometimes cause acute kidney injury (AKI), a sudden and serious decline in kidney function.

A review of data from over 7,000 patients found that spacing out the procedures did not change the overall rate of kidney issues compared to doing everything at once. However, there was a specific difference for more severe cases. The staged approach showed a statistically significant benefit for patients who suffered from stage 3 or 4 kidney injury.

While the results are promising for preventing severe damage, it is important to note that the data showed some inconsistency across different studies. Staged procedures do not consistently reduce all types of kidney issues, but they may offer specific protection against the most severe forms.

What this means for you:
Staged heart procedures may specifically reduce the risk of severe stage 3 or 4 kidney injury during TAVR.

Common questions

What is the difference between staged and concomitant PCI?

Concomitant means performing both treatments at the same time during one procedure. Staged means performing the procedures at different times. This study looked at these two methods to see which was safer for a patient's kidneys when they were undergoing TAVR surgery.

Does spacing out the procedures reduce all types of kidney damage?

No, the data showed that staged procedures did not significantly differ from concurrent ones for overall kidney injury or stage 1 and stage 2 issues. However, a statistically significant difference was found specifically favoring the staged approach for more severe cases, known as stage 3 and 4 kidney injury.

Is it safer to space out procedures for every patient?

The study shows that while staging may offer benefits for preventing severe stage 3 or 4 kidney injury, it does not consistently reduce all types of kidney issues. Because results vary and the data showed some inconsistency, you should talk to your doctor about which approach is best for your specific health needs.

Study Details

Study typeMeta analysis
Sample sizen = 7,119
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Background: The optimal timing of percutaneous coronary intervention (PCI) in patients undergoing transcatheter aortic valve replacement (TAVR) remains unclear, particularly regarding its impact on renal outcomes. Methods: We conducted systematic review and meta-analysis of studies comparing staged versus concomitant PCI in patients with aortic stenosis and coronary artery disease undergoing TAVR. We searched MEDLINE, Embase, and Cochrane databases comprehensively. Using a random-effects model, we calculated odds ratios (OR) with 95% confidence intervals (CI) to assess the incidence of contrast-induced acute coronary injury (CI-AKI) across different stages. Results: The analysis included 11 studies encompassing 7,119 patients. Overall, staged PCI did not significantly differ from concomitant PCI in reducing CI-AKI (OR 1.02; 95% CI 0.53 to 1.98; p = 0.959; Figure 2A). Subgroup analysis revealed no significant differences in stage 1 (OR 1.99; 95% CI 0.38 to 10.47; p = 0.417; Figure 2B) or stage 2 CI-AKI (OR 1.01; 95% CI 0.39 to 2.64; p = 0.978; Figure 2C). However, a statistically significant difference emerged for stage 3/4 CI-AKI, favoring the staged approach (OR 0.48; 95% CI 0.24 to 0.99; p = 0.046; Figure 2D). Conclusion: While staged PCI does not consistently reduce CI-AKI in patients undergoing TAVR, it may offer potential benefits for more severe kidney injury (stages 3/4). Given the observed heterogeneity, large-scale randomized controlled trials are essential to establish the relationship between procedural timing and renal outcomes.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.